ABBV Abbvie Inc

$ABBV $VKTX $ABBV headline data today on GUBRA amylin presentation. Someone probably will provide slides. But no details on all AEs and 4.4% placebo adjusted DC due to GI AE is not good for an amylin. It’s higher than what reported with leading incretins $LLY TZP and $VKTX 2735 Half life 10-12 days is C/W with what available out there from other mechanisms as CEO continues to mull combination ( which doesn’t seem to be a good idea with this amylin based on above )

Just like yesterday, the stocks making new 52-week relative strength high vs the S&P 500 are defensive healthcare and consumer staples stocks like $ABBV $BIIB $KO etc.

$ABBV Regardless if we are in a recession or not people are always going to get sick and medicine is going to be needed around the world 🌏🌎🌍 we are still early with $ABBV

$ABBV $KURA $SNDX This is a hematologist prescriber survey embedded within the recent SNDX note, focused on NPM1 mutant AML (the largest subset of adult AML, ~30% of all AML). Core survey findings 1. Diagnosis & testing behavior Virtually all responding leukemia specialists now routinely test newly diagnosed AML patients for NPM1 mutation at baseline. Previously, many viewed revumenib only as a KMT2Ar drug; survey shows this perception has shifted after NPM1 label approval + real-world data. 2. Treatment preference for R/R NPM1 AML (already approved setting) ◦ Efficacy / deep MRD response is the #1 decision factor (ranked far above safety, oral convenience, or price). ◦ HCPs say revumenib’s ability to drive MRD negativity is its biggest differentiator vs older salvage regimens. ◦ Survey uptake expectation: Respondents expect Revuforj to capture a dominant share of eligible R/R NPM1 patients, even with competing menin inhibitor now on market.

The Nasdaq dropped 1.9% yesterday. $ABBV closed at a record high. This morning it pushed through 285.40, tagging 290.56. Now the job is holding above 285.40 into the close. That's what I'm watching.

$ABBV I’ve just stubbornly held this since the spin out in 2013 collecting dividends and capital appreciation the entire way instead of trying to trade it like the day flippers and hedge funds. A good lesson for the kids out there!

$ABBV I at least added this yesterday, 274.94 ath. But made more mistakes yesterday than any day the last three months. So many false breakouts.

$ABBV What a monster stock this has been ... now consolidating over the base for potential next leg up

$ABBV: the Juvederm suit cites a 2022 study putting delayed nodules at 0.5% to 0.98% for the filler family, higher than rivals. It alleges AbbVie never warned of granulomas. No class certified, nothing to claim. Open Class Actions.

$ABBV AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio "New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicine"

$ABBV $AAPL Market seems to rotating from the fraud AI complex into real companies like ABBV and AAPL.

$ABBV $MRK $PFE I normally avoid posting on my big pharma holding boards because they are small cap bio pump sesspools, but nice day!!

$ABBV (AbbVie) gets FDA approval for tavapadon (brand name Juvmo), a once-daily pill for Parkinson's disease, with the drug acquired through AbbVie's 2023 purchase of Cerevel Therapeutics.

$ABBV (AbbVie) announces a multi-year collaboration with Iambic to accelerate AI-driven drug discovery in immunology, neuroscience, and oncology, leveraging Iambic's molecular superintelligence platform to shorten drug discovery timelines.

$ABBV $IAM $NVDA I hope you’re buying. Triple digits by next week. Cathie Woods now holds 20% of the shares. Locked. No shorts. IPO. Huge backers

$ABBV $IAM $NVDA follow my posts about this company! $NVDA and $ABBV are partners, true partners. AND Woods now owns 20% of the shares. No shorts no offerings no bs.

$ABBV: keep your Juvederm receipts. Garcia v. AbbVie seeks economic damages, the price premium patients allegedly paid, not just injury claims. Four classes are proposed, none certified, nothing to claim. Open Class Actions.

$ABBV - way overbought…algos might rotate back to tech before close…expect sell off in bio tech tomorrow….near term 270…$JNJ $AMGN

$ABBV: the lead plaintiff in Garcia v. AbbVie says she paid thousands out of pocket for Juvederm in 2023, then was hospitalized 3 years later from alleged delayed granulomas. No class certified, nothing to claim. Open Class Actions.

$ABBV $280.72 ath. And that’s about my only highlight today. $PENG also moving well but I don’t have much left.